RARE CANCER AGENDA 2030 Ten Recommendations from the EU Joint Action on Rare Cancers 1. Rare cancers are the rare diseases of oncology 2. Rare cancers should be monitored 3. Health systems should exploit networking 4. Medical education should exploit and serve healthcare networking 5. Research should be fostered by networking and should take into account an expected higher degree of uncertainty 6. Patient-physician shared clinical decision-making should be especially valued 7. Appropriate state-of-the-art instruments should be developed in rare cancer 8. Regulation on rare cancers should tolerate a higher degree of uncertainty 9. Policy strategies on rare cancers and sustainability of interventions should be based on networking 10. Rare cancer patients should be engaged

The fifth edition of the only comprehensive text dealing exclusively with rare or infrequently encountered malignancies in adults and children is an essential resource for any clinical oncologist. Encompasses all the information needed to diagnose and manage uncommon cancers, an area where advice and guidance is typically scarce Fully revised with new material and an evidence-based, teach-by-example approach Provides insight on real-world decision making in the clinical setting Edited and authored by a highly experienced and senior team of medical oncologists, radiation oncologists, and other specialists, giving a balanced and complete overview Extensively illustrated in full color throughout, including heat maps to show gene expression

Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.

Data obtained by population based cancer registries have a pivotal role in cancer control. Now also available in Spanish and French, this volume, which contains 15 authored chapters and four useful appendices, remains a standard reference for those planning to establish new cancer registries and those keen to adopt recognized methodologies. Information is given on the techniques required to collect, store, analyse and interpret data.

Rare Genitourinary Tumors offers the reader an up-to-date discussion of the less common neoplasms affecting the urinary tract and reproductive organs. Each authoritative chapter provides and in-depth discussion that is frequently not found in other urologic oncology textbooks. A valuable reference for urologists, oncologists, and those in specialty training, this volume provides ready access to information on etiology, incidence, risk factors, diagnosis, prognosis, insights from molecular pathology and, where applicable, data from clinical trials. The practical treatment guidelines included for each tumor type are written by experts and fully referenced.

This book provides clinicians with clear guidance on treatment decision-making in patients with rare kidney cancers. After a brief review on epidemiology, pathology, and biology, each chapter focuses on the multidisciplinary management of a particular tumor subtype using the full range of available cancer therapy modalities, including surgery, radiotherapy, chemotherapy, targeted therapies, and immunotherapy. Emerging therapies and future directions in the management of each cancer subtype are also discussed. The chapters are all written by multidisciplinary teams of international experts comprising at least a urologist, a medical oncologist, and a pathologist. Rare kidney cancers represent 15% of renal cell carcinomas. In comparison with clear cell renal cell carcinomas, little is known about the biology of such cancers, and few trials have reported on the efficacy of targeted therapies in the metastatic setting. Optimal management thus poses significant challenges and often requires a multidisciplinary team. This book will be an ideal reference guide for all clinicians involved in the care of patients with these orphan tumors.

It has been recognized for almost 200 years that certain families seem to inherit cancer. It is only in the past decade, however, that molecular genetics and epidemiology have combined to define the role of inheritance in cancer more clearly, and to identify some of the genes involved. The causative genes can be tracked through cancer-prone families via genetic linkage and positional cloning. Several of the genes discovered have subsequently been proved to play critical roles in normal growth and development. There are also implications for the families themselves in terms of genetic testing with its attendant dilemmas, if it is not clear that useful action will result. The chapters in The Genetics of Cancer illustrate what has already been achieved and take a critical look at the future directions of this research and its potential clinical applications.